Traws Pharma: ratutrelvir Phase 2 shows fewer AEs, faster symptom resolution; FDA hold on tivoxavir IND

Traws Pharma, Inc.

Ratutrelvir Phase 2: 10% vs 23.3% adverse events, faster symptom resolution (HR 1.31, p=0.018), no viral rebound vs PAXLOVID.
Ratutrelvir showed benefit in PAXLOVID-ineligible patients, addressing unmet need in high-risk COVID-19 population.
Tivoxavir marboxil tablet formulation showed 30% increased pre-clinical exposure, modeled 28-day monthly prophylaxis.
FDA placed US IND for tivoxavir marboxil on clinical hold due to mutagenicity concerns; formal communication by March 16, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.